ID

44367

Descrição

A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT00814606

Link

https://clinicaltrials.gov/show/NCT00814606

Palavras-chave

Versões (2)
  1. 31/01/2020 31/01/2020 -
  2. 20/09/2021 20/09/2021 -
Titular dos direitos

See clinicaltrials.gov

Transferido a

20 de setembro de 2021

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Hepatitis C NCT00814606

Inglês

Eligibility Hepatitis C NCT00814606

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
male or female of any ethnicity age 18 - 65 years with genotype 1 hcv
Descrição

Ethnicity Any | Age | Hepatitis C Genotype

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0015031
UMLS CUI [1,2]
C1552551
UMLS CUI [2]
C0001779
UMLS CUI [3,1]
C0019196
UMLS CUI [3,2]
C1533728
previous partial responder to attempts at hcv therapy with peg/rbv (at least 1 log drop but less than 2 log drop in hcv rna at 12 weeks)
Descrição

Partial responder to therapy Hepatitis C | PEGINTERFERON/RIBAVIRIN | Hepatitis C virus RNA Assay

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1740822
UMLS CUI [1,2]
C0019196
UMLS CUI [2]
C1875630
UMLS CUI [3,1]
C0369335
UMLS CUI [3,2]
C1510438
previous history or serum hcv-rna pcr quantifiable by roche amplicore hcv test
Descrição

Hepatitis C virus RNA Polymerase Chain Reaction | Other Coding

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0369335
UMLS CUI [1,2]
C0032520
UMLS CUI [2]
C3846158
a liver biopsy within 3 years of study enrollment consistent with hcv disease.
Descrição

Biopsy of liver Consistent with Hepatitis C

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0193388
UMLS CUI [1,2]
C0332290
UMLS CUI [1,3]
C0019196
compensated liver disease, child-pugh class ≤ 6
Descrição

Compensated liver disease Child-Pugh Classification

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C3839044
UMLS CUI [1,2]
C4050412
negative urine pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of the study drug
Descrição

Childbearing Potential Urine pregnancy test negative

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0430057
all patients enrolling in the study and all partners of study participants of childbearing potential must be using two reliable forms of effective contraception during the study. exceptions may include partner/participant is surgically sterile.
Descrição

Study Subject All Contraceptive methods Quantity | Partner Childbearing Potential Contraceptive methods Quantity | Exception Partner Sexual sterilization | Exception Study Subject Sexual sterilization

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C0444868
UMLS CUI [1,3]
C0700589
UMLS CUI [1,4]
C1265611
UMLS CUI [2,1]
C0682323
UMLS CUI [2,2]
C3831118
UMLS CUI [2,3]
C0700589
UMLS CUI [2,4]
C1265611
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0682323
UMLS CUI [3,3]
C0038288
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0681850
UMLS CUI [4,3]
C0038288
willingness to comply with study procedures and provide written informed consent
Descrição

Protocol Compliance | Informed Consent

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0525058
UMLS CUI [2]
C0021430
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
ast or alt > 10 uln
Descrição

Aspartate aminotransferase increased | Alanine aminotransferase increased

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0151904
UMLS CUI [2]
C0151905
any investigational drug ≤ 12 weeks prior to the first of study drug
Descrição

Investigational New Drugs

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0013230
prior intolerance to statin medications
Descrição

Intolerance to Statins

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1744706
UMLS CUI [1,2]
C0360714
previous serious side effects to ifn or rbv (e.g. psychiatric side effect necessitating treatment discontinuation, severe cytopenia refractory to growth factors, intolerance to ifn/rbv requiring treatment discontinuation)
Descrição

Side effects Serious Interferon | Side effects Serious Ribavirin | Side effects Psychiatric | Requirement Treatment Discontinuation | Cytopenia Severe | Unresponsive to Growth Factors | Intolerance to Interferon | Intolerance to Ribavirin

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0879626
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0021747
UMLS CUI [2,1]
C0879626
UMLS CUI [2,2]
C0205404
UMLS CUI [2,3]
C0035525
UMLS CUI [3,1]
C0879626
UMLS CUI [3,2]
C0205487
UMLS CUI [4,1]
C1514873
UMLS CUI [4,2]
C0087111
UMLS CUI [4,3]
C0457454
UMLS CUI [5,1]
C0010828
UMLS CUI [5,2]
C0205082
UMLS CUI [6,1]
C0205269
UMLS CUI [6,2]
C0018284
UMLS CUI [7,1]
C1744706
UMLS CUI [7,2]
C0021747
UMLS CUI [8,1]
C1744706
UMLS CUI [8,2]
C0035525
any systemic antiviral therapy ≤ 24 weeks prior to the first dose of study drug or expectation that such treatment will be needed at any time during the study. exception: patients who have taken or are expected to require such treatment for herpetic lesions
Descrição

Antiviral Therapy Systemic | Antiviral Therapy Systemic Expected | Exception Treatment Lesion of liver

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0280274
UMLS CUI [1,2]
C0205373
UMLS CUI [2,1]
C0280274
UMLS CUI [2,2]
C0205373
UMLS CUI [2,3]
C1517001
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0087111
UMLS CUI [3,3]
C0577053
positive test at screening for anti-hav igm ab, hbsag, anti-hbc-igm ab ,or anti-hiv ab
Descrição

Hepatitis A virus IgM antibody positive | Hepatitis B surface antigen positive | Anti-HBc IgM antibody positive | HIV Antibodies Positive

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1096503
UMLS CUI [2]
C0149709
UMLS CUI [3]
C1096146
UMLS CUI [4,1]
C0019683
UMLS CUI [4,2]
C1514241
serum concentrations of cerulplamin or alph-1-antitrypsin consistent with an increased risk of metabolic liver disease
Descrição

Serum ceruloplasmin level result At risk Liver disease Metabolic | Alpha-1-antitrypsin measurement At risk Liver disease Metabolic

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1318404
UMLS CUI [1,2]
C1444641
UMLS CUI [1,3]
C0023895
UMLS CUI [1,4]
C0311400
UMLS CUI [2,1]
C0201856
UMLS CUI [2,2]
C1444641
UMLS CUI [2,3]
C0023895
UMLS CUI [2,4]
C0311400
history or other evidence of a medical condition associated with chronic liver disease (e.g. hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposure, nonalcoholic steatohepatitis)
Descrição

Medical condition Associated with Chronic liver disease | Hemochromatosis | Hepatitis, Autoimmune | Alcoholic Liver Disease | Exposure to toxin | Nonalcoholic Steatohepatitis

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0332281
UMLS CUI [1,3]
C0341439
UMLS CUI [2]
C0018995
UMLS CUI [3]
C0241910
UMLS CUI [4]
C0023896
UMLS CUI [5]
C0040537
UMLS CUI [6]
C3241937
women who are pregnant or breastfeeding and male partners of woman who are pregnant or breastfeeding
Descrição

Pregnancy | Breast Feeding | Gender Partner Pregnancy | Gender Partner Breast Feeding

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C0079399
UMLS CUI [3,2]
C0682323
UMLS CUI [3,3]
C0032961
UMLS CUI [4,1]
C0079399
UMLS CUI [4,2]
C0682323
UMLS CUI [4,3]
C0006147
Voltar ao início da página

Similar models

Eligibility Hepatitis C NCT00814606

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Ethnicity Any | Age | Hepatitis C Genotype
Item
male or female of any ethnicity age 18 - 65 years with genotype 1 hcv
boolean
C0015031 (UMLS CUI [1,1])
C1552551 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2])
C0019196 (UMLS CUI [3,1])
C1533728 (UMLS CUI [3,2])
Partial responder to therapy Hepatitis C | PEGINTERFERON/RIBAVIRIN | Hepatitis C virus RNA Assay
Item
previous partial responder to attempts at hcv therapy with peg/rbv (at least 1 log drop but less than 2 log drop in hcv rna at 12 weeks)
boolean
C1740822 (UMLS CUI [1,1])
C0019196 (UMLS CUI [1,2])
C1875630 (UMLS CUI [2])
C0369335 (UMLS CUI [3,1])
C1510438 (UMLS CUI [3,2])
Hepatitis C virus RNA Polymerase Chain Reaction | Other Coding
Item
previous history or serum hcv-rna pcr quantifiable by roche amplicore hcv test
boolean
C0369335 (UMLS CUI [1,1])
C0032520 (UMLS CUI [1,2])
C3846158 (UMLS CUI [2])
Biopsy of liver Consistent with Hepatitis C
Item
a liver biopsy within 3 years of study enrollment consistent with hcv disease.
boolean
C0193388 (UMLS CUI [1,1])
C0332290 (UMLS CUI [1,2])
C0019196 (UMLS CUI [1,3])
Compensated liver disease Child-Pugh Classification
Item
compensated liver disease, child-pugh class ≤ 6
boolean
C3839044 (UMLS CUI [1,1])
C4050412 (UMLS CUI [1,2])
Childbearing Potential Urine pregnancy test negative
Item
negative urine pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of the study drug
boolean
C3831118 (UMLS CUI [1,1])
C0430057 (UMLS CUI [1,2])
Study Subject All Contraceptive methods Quantity | Partner Childbearing Potential Contraceptive methods Quantity | Exception Partner Sexual sterilization | Exception Study Subject Sexual sterilization
Item
all patients enrolling in the study and all partners of study participants of childbearing potential must be using two reliable forms of effective contraception during the study. exceptions may include partner/participant is surgically sterile.
boolean
C0681850 (UMLS CUI [1,1])
C0444868 (UMLS CUI [1,2])
C0700589 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,4])
C0682323 (UMLS CUI [2,1])
C3831118 (UMLS CUI [2,2])
C0700589 (UMLS CUI [2,3])
C1265611 (UMLS CUI [2,4])
C1705847 (UMLS CUI [3,1])
C0682323 (UMLS CUI [3,2])
C0038288 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0681850 (UMLS CUI [4,2])
C0038288 (UMLS CUI [4,3])
Protocol Compliance | Informed Consent
Item
willingness to comply with study procedures and provide written informed consent
boolean
C0525058 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Aspartate aminotransferase increased | Alanine aminotransferase increased
Item
ast or alt > 10 uln
boolean
C0151904 (UMLS CUI [1])
C0151905 (UMLS CUI [2])
Investigational New Drugs
Item
any investigational drug ≤ 12 weeks prior to the first of study drug
boolean
C0013230 (UMLS CUI [1])
Intolerance to Statins
Item
prior intolerance to statin medications
boolean
C1744706 (UMLS CUI [1,1])
C0360714 (UMLS CUI [1,2])
Side effects Serious Interferon | Side effects Serious Ribavirin | Side effects Psychiatric | Requirement Treatment Discontinuation | Cytopenia Severe | Unresponsive to Growth Factors | Intolerance to Interferon | Intolerance to Ribavirin
Item
previous serious side effects to ifn or rbv (e.g. psychiatric side effect necessitating treatment discontinuation, severe cytopenia refractory to growth factors, intolerance to ifn/rbv requiring treatment discontinuation)
boolean
C0879626 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0021747 (UMLS CUI [1,3])
C0879626 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C0035525 (UMLS CUI [2,3])
C0879626 (UMLS CUI [3,1])
C0205487 (UMLS CUI [3,2])
C1514873 (UMLS CUI [4,1])
C0087111 (UMLS CUI [4,2])
C0457454 (UMLS CUI [4,3])
C0010828 (UMLS CUI [5,1])
C0205082 (UMLS CUI [5,2])
C0205269 (UMLS CUI [6,1])
C0018284 (UMLS CUI [6,2])
C1744706 (UMLS CUI [7,1])
C0021747 (UMLS CUI [7,2])
C1744706 (UMLS CUI [8,1])
C0035525 (UMLS CUI [8,2])
Antiviral Therapy Systemic | Antiviral Therapy Systemic Expected | Exception Treatment Lesion of liver
Item
any systemic antiviral therapy ≤ 24 weeks prior to the first dose of study drug or expectation that such treatment will be needed at any time during the study. exception: patients who have taken or are expected to require such treatment for herpetic lesions
boolean
C0280274 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0280274 (UMLS CUI [2,1])
C0205373 (UMLS CUI [2,2])
C1517001 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0087111 (UMLS CUI [3,2])
C0577053 (UMLS CUI [3,3])
Hepatitis A virus IgM antibody positive | Hepatitis B surface antigen positive | Anti-HBc IgM antibody positive | HIV Antibodies Positive
Item
positive test at screening for anti-hav igm ab, hbsag, anti-hbc-igm ab ,or anti-hiv ab
boolean
C1096503 (UMLS CUI [1])
C0149709 (UMLS CUI [2])
C1096146 (UMLS CUI [3])
C0019683 (UMLS CUI [4,1])
C1514241 (UMLS CUI [4,2])
Serum ceruloplasmin level result At risk Liver disease Metabolic | Alpha-1-antitrypsin measurement At risk Liver disease Metabolic
Item
serum concentrations of cerulplamin or alph-1-antitrypsin consistent with an increased risk of metabolic liver disease
boolean
C1318404 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C0023895 (UMLS CUI [1,3])
C0311400 (UMLS CUI [1,4])
C0201856 (UMLS CUI [2,1])
C1444641 (UMLS CUI [2,2])
C0023895 (UMLS CUI [2,3])
C0311400 (UMLS CUI [2,4])
Medical condition Associated with Chronic liver disease | Hemochromatosis | Hepatitis, Autoimmune | Alcoholic Liver Disease | Exposure to toxin | Nonalcoholic Steatohepatitis
Item
history or other evidence of a medical condition associated with chronic liver disease (e.g. hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposure, nonalcoholic steatohepatitis)
boolean
C3843040 (UMLS CUI [1,1])
C0332281 (UMLS CUI [1,2])
C0341439 (UMLS CUI [1,3])
C0018995 (UMLS CUI [2])
C0241910 (UMLS CUI [3])
C0023896 (UMLS CUI [4])
C0040537 (UMLS CUI [5])
C3241937 (UMLS CUI [6])
Pregnancy | Breast Feeding | Gender Partner Pregnancy | Gender Partner Breast Feeding
Item
women who are pregnant or breastfeeding and male partners of woman who are pregnant or breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0079399 (UMLS CUI [3,1])
C0682323 (UMLS CUI [3,2])
C0032961 (UMLS CUI [3,3])
C0079399 (UMLS CUI [4,1])
C0682323 (UMLS CUI [4,2])
C0006147 (UMLS CUI [4,3])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial